Jpmorgan Chase & CO Summit Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 162,649 shares of SMMT stock, worth $3.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
162,649
Previous 163,750
0.67%
Holding current value
$3.17 Million
Previous $1.28 Million
178.94%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SMMT
# of Institutions
194Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$476 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$213 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$154 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$106 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$67.5 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.92B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...